Table 5.
Postoperative Outcomes and Serum anti-TNFα Drug Levels in Study Cohort
| Study Cohort (n=217) |
Undetectable Level (n=150) |
Detectable Level (n=67) |
Low Level (n=6) |
Medium Level (n=17) |
High Level (n=44) |
|
|---|---|---|---|---|---|---|
| Postoperative morbidity | 68 (31) | 44 (29) | 24 (36) | 1 (17) | 7 (41) | 16 (36) |
| Medical complications | 26 (12) | 14 (9) | 12 (18) | 1 (17) | 5 (29) | 6 (14) |
| Major | 11 (5) | 5 (3) | 6 (9) | 0 | 4 (24) | 2 (4) |
| Minor | 15 (7) | 9 (6) | 6 (9) | 1 (17) | 1 (6) | 4 (9) |
| Surgical complications | 51 (24) | 36 (24) | 15 (22) | 0 | 3 (18) | 12 (27) |
| Major | 19 (9) | 13 (9) | 6 (9) | 0 | 2 (12) | 4 (9) |
| Minor | 32 (15) | 23 (15) | 9 (13) | 0 | 1 (6) | 8 (18) |
| Infectious complications | 30 (14) | 17 (11) | 13 (19) | 1 (17) | 3 (18) | 9 (20) |
| Postoperative mortality | 1 (1) | 0 | 1 (1) | 0 | 1 (6) | 0 |
| Mean postoperative LOS (d) | 5.6 (2.5) | 5.8 (2.6) | 5.2 (2.2) | 5.3 (1.4) | 4.7 (1.9) | 5.4 (2.4) |
| Readmission within 30 days | 32 (15) | 20 (13) | 12 (18) | 0 | 3 (18) | 9 (20) |
All values in parentheses denote % except postoperative length of stay (standard deviation)
LOS length of stay
All p=